Uche Nkechinyere J, Okoye Onochie, Okoye Obiekwe, Oguegbu I, Uche Enoch O
Department of Ophthalmology, University of Nigeria Teaching Hospital Ituku/Ozalla, Enugu, Nigeria.
Neurosurgery Unit, Department of Surgery, University of Nigeria Teaching Hospital Ituku/Ozalla Enugu, Enugu, Nigeria.
Rare Tumors. 2022 Feb 23;14:20363613221079763. doi: 10.1177/20363613221079763. eCollection 2022.
Orbito-ocular tumors are rare, but they cause significant morbidity and mortality. There are reported variations in their pattern of presentation and frequency of occurrence.
To evaluate the occurrence, clinico-pathologic spectrum, and patterns of orbito-ocular neoplasms as well as the treatment and outcome profiles.
A 5-year retrospective analysis of consecutive patients treated for orbito-ocular tumors. We evaluated patterns of occurrence, clinic-pathological concordance, and outcome of treatment. Associations were evaluated with chi square and confidence interval. Data analysis was performed using SPSS for windows version 23 and inferences were judged using the 95% level of significance.
Among 100 patients with orbito-ocular masses, 62 were histologically confirmed. The female to male ratio (F:M) was 1.0. Their ages ranged from 7 months to 93 years, mean = 33.4 ± 2.7 years. There was an age variation among tumor types. Patients with squamous cell carcinoma (SCC) had a mean age of 46.4 years, while for retinoblastoma the mean age was 3.09 years. All patients with retinoblastoma had proven macroscopic orbital extension. SCC was the most common tumor type ( = 19), however, among children, retinoblastoma ( = 11) was more common. Melanocytic nevus, sebaceous gland carcinoma, and adenocarcinoma of lacrimal gland ( = 6, = 5, = 5), respectively, among other tumors were treated. Concordance between clinical and histopathological diagnoses was obtained among 30 (48.3%) cases. 1-year and 3-year survival for retinoblastoma was 90% and 72.9%, respectively, and 78.9% and 68.4% for SCC.
SCC is currently the most common orbito-ocular tumor in our setting.
眼眶-眼肿瘤较为罕见,但会导致严重的发病率和死亡率。据报道,其临床表现模式和发生频率存在差异。
评估眼眶-眼肿瘤的发生情况、临床病理谱、模式以及治疗和结局情况。
对连续治疗的眼眶-眼肿瘤患者进行5年回顾性分析。我们评估了发生模式、临床病理一致性和治疗结局。采用卡方检验和置信区间评估相关性。使用SPSS for windows 23版进行数据分析,并以95%的显著性水平判断推论。
在100例眼眶-眼肿物患者中,62例经组织学确诊。男女比例(F:M)为1.0。年龄范围为7个月至93岁,平均年龄 = 33.4 ± 2.7岁。不同肿瘤类型之间存在年龄差异。鳞状细胞癌(SCC)患者的平均年龄为46.4岁,而视网膜母细胞瘤的平均年龄为3.09岁。所有视网膜母细胞瘤患者均证实有肉眼可见的眼眶扩展。SCC是最常见的肿瘤类型( = 19),然而,在儿童中,视网膜母细胞瘤( = 11)更为常见。还分别治疗了黑素细胞痣、皮脂腺癌和泪腺腺癌( = 6, = 5, =5)等其他肿瘤。30例(48.3%)病例的临床诊断与组织病理学诊断一致。视网膜母细胞瘤的1年和3年生存率分别为90%和72.9%,SCC分别为78.9%和68.4%。
在我们的研究中,SCC目前是最常见的眼眶-眼肿瘤。